What Should US Policymakers Learn From International Drug Pricing Transparency Strategies
Bibliographic Data
| ID | 15744543 |
|---|---|
| Authors | Sarosh Nagar (0000-0002-4534-6561, Brigham and Women's Hospital, corresponding author), Leah Z Rand (0000-0003-3262-1584, Brigham and Women's Hospital), Aaron S Kesselheim (0000-0002-8867-2666, Brigham and Women's Hospital) |
| Year | 2022 |
| Volume | 24 |
| Issue | 11 |
| Pages | E1083-1090 |
| Publication date | 2022-11-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | The AMA Journal of Ethic (JOURNAL) |
| Journal identifiers | ISSN: 2376-6980 • E-ISSN: 2376-6980 |
| Publisher | American Medical Association (PUBLISHER • US) |
| DOI | 10.1001/amajethics.2022.1083 |
| PMID | 36342492 |
| OpenAlex | W4308640071 |
| Language | EN |
| Citations received | 1 |
| References cited | 3 |
This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation for Economic Co-operation and Development member nations: the United Kingdom, Germany, and Canada. Specifically, this article compares these countries' policies on list and net price disclosures and on how international reference pricing is used to evaluate merits and drawbacks of different pricing transparency approaches. Finally, the article summarizes what policymakers in the United States should learn from these comparisons
Actuarial science · Business · Drug pricing · Economics · Political science · Public economics · Transparency (behavior · Healthcare Policy and Management · Law · Pharmaceutical Economics and Policy · Pharmaceutical industry and healthcare · Accounting
| Unique citing works | 1 |
|---|---|
| Citations per year | 0.25 |
| Citation span | 2022 - 2022 (1) |
| Citation velocity | historical |
| Highly cited | No |
| Citation types | Neutral: 1 |